The Asia Pacific Degenerative Disc Disease Treatment Market would witness market growth of 5.9% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Degenerative Disc Disease Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $3.01 billion by 2031. The Japan market is registering a CAGR of 5.2% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 6.6% during (2024 - 2031).
Platelet-rich plasma (PRP) therapy injects concentrated platelets derived from the patient's blood into the affected disc area. It promotes tissue healing and reduces inflammation, potentially slowing down the progression of disc degeneration. Stem cells derived from bone marrow or adipose tissue may be injected into the degenerated disc to stimulate tissue repair and regeneration. This emerging therapy holds promise for restoring disc function and reducing pain.
Moreover, spinal manipulation and adjustments performed by chiropractors can help improve spinal alignment, reduce pain, and enhance mobility for some individuals with DDD. This traditional Chinese medicine technique involves inserting thin needles into specific points on the body to alleviate pain and promote healing. Therapeutic massage techniques can help relax muscles, improve circulation, and reduce muscle tension associated with DDD.
The growth of the hospital sector drives investments in technological advancements in DDD treatment. This includes adopting minimally invasive surgical techniques, robotic-assisted surgeries, and innovative therapies to improve surgical outcomes and patient recovery times. The expansion of hospitals in India led to the establishment of dedicated spine centers and orthopedic departments equipped with advanced diagnostic tools such as MRI and CT scans. This facilitates early and accurate diagnosis of DDD, enabling timely intervention and treatment planning. Therefore, the rising hospital sector and the region's high rates of spinal problems are driving the market's growth.
Based on Route of Administration, the market is segmented into Oral, and Injectable. Based on Drugs, the market is segmented into NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Acetaminophen, Muscle Relaxants, and Steroids. Based on End Use, the market is segmented into Hospitals, Clinics, and Others. Based on Treatment Type, the market is segmented into Physical Therapy, Occupational Therapy, Special Exercises, Weight Loss Surgery, and Medications. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The China market dominated the Asia Pacific Degenerative Disc Disease Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $3.01 billion by 2031. The Japan market is registering a CAGR of 5.2% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 6.6% during (2024 - 2031).
Platelet-rich plasma (PRP) therapy injects concentrated platelets derived from the patient's blood into the affected disc area. It promotes tissue healing and reduces inflammation, potentially slowing down the progression of disc degeneration. Stem cells derived from bone marrow or adipose tissue may be injected into the degenerated disc to stimulate tissue repair and regeneration. This emerging therapy holds promise for restoring disc function and reducing pain.
Moreover, spinal manipulation and adjustments performed by chiropractors can help improve spinal alignment, reduce pain, and enhance mobility for some individuals with DDD. This traditional Chinese medicine technique involves inserting thin needles into specific points on the body to alleviate pain and promote healing. Therapeutic massage techniques can help relax muscles, improve circulation, and reduce muscle tension associated with DDD.
The growth of the hospital sector drives investments in technological advancements in DDD treatment. This includes adopting minimally invasive surgical techniques, robotic-assisted surgeries, and innovative therapies to improve surgical outcomes and patient recovery times. The expansion of hospitals in India led to the establishment of dedicated spine centers and orthopedic departments equipped with advanced diagnostic tools such as MRI and CT scans. This facilitates early and accurate diagnosis of DDD, enabling timely intervention and treatment planning. Therefore, the rising hospital sector and the region's high rates of spinal problems are driving the market's growth.
Based on Route of Administration, the market is segmented into Oral, and Injectable. Based on Drugs, the market is segmented into NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Acetaminophen, Muscle Relaxants, and Steroids. Based on End Use, the market is segmented into Hospitals, Clinics, and Others. Based on Treatment Type, the market is segmented into Physical Therapy, Occupational Therapy, Special Exercises, Weight Loss Surgery, and Medications. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- Medtronic PLC
- AstraZeneca PLC
- Pfizer, Inc.
- Novartis AG
- Eli Lilly And Company
- Spine Wave Inc.
- Braun Melsungen AG (Aesculap, Inc.)
- DiscGenics, Inc.
- Spine BioPharma Inc.
- Stryker Corporation
Market Report Segmentation
By Route of Administration- Oral
- Injectable
- NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- Acetaminophen
- Muscle Relaxants
- Steroids
- Hospitals
- Clinics
- Others
- Physical Therapy
- Occupational Therapy
- Special Exercises
- Weight Loss Surgery
- Medications
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Degenerative Disc Disease Treatment Market by Route of Administration
Chapter 5. Asia Pacific Degenerative Disc Disease Treatment Market by Drugs
Chapter 6. Asia Pacific Degenerative Disc Disease Treatment Market by End Use
Chapter 7. Asia Pacific Degenerative Disc Disease Treatment Market by Treatment Type
Chapter 8. Asia Pacific Degenerative Disc Disease Treatment Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Medtronic PLC
- AstraZeneca PLC
- Pfizer, Inc.
- Novartis AG
- Eli Lilly And Company
- Spine Wave Inc.
- B. Braun Melsungen AG (Aesculap, Inc.)
- DiscGenics, Inc.
- Spine BioPharma Inc.
- Stryker Corporation
Methodology
LOADING...
